New clinical trials seek treatments for canine cancers, may offer clues on human cancers

October 11, 2018, Tufts University
Hazel, an osteosarcoma patient, visits Foster Hospital for Small Animals at Cummings Veterinary Medical Center at Tufts University to participate in a clinical trial. Credit: Tufts University

Two studies into deadly cancers in dogs are now underway, offered through the newly formed Clinical Trials Office at Cummings Veterinary Medical Center at Tufts University. Dogs with spontaneous osteosarcoma, as well as dogs with mast cell tumors and solid tumors, may be eligible for enrollment.

Each year, nearly 500 companion animals participate in voluntary clinical trials at Cummings Veterinary Medical Center, with 30-40 studies enrolling patients at a given time. While several of these trials serve to gather information and test therapies for diseases and conditions found specifically in animals, over a dozen current trials are focused on diseases that occur in both animals and humans.

"Dogs share many physiological similarities to humans, are exposed to the same environment and get many of the same diseases, like osteosarcoma, a malignant of bone that occurs in both and adolescents," said Cheryl London, DVM, Ph.D., ACVIM (Oncology), director of the Clinical Trials Office. "Studying these naturally-occurring diseases in dogs and other companion animals—a growing field known as comparative medicine—helps provide researchers and medical professionals with important information to potentially advance development of therapies for treatment in both species," added London, Anne Engen and Dusty Professor of Comparative Oncology at Cummings School of Veterinary Medicine at Tufts University.

With a greater than 80% percent failure rate for cancer drug trials in humans, the opportunity to learn more about effectiveness of treatments and possible side effects in companion could more quickly and cost-effectively advance human drugs to market, and help along the way, said London.

Participation in at Cummings Veterinary Medical Center is voluntary for pet owners and typically includes coverage of all medical costs directly related to the trial.

More information on two of the in canine cancer is available below:

Canine Osteosarcoma

This clinical trial evaluates the effectiveness of new immunotherapy combinations for dogs with osteosarcoma that has spread to the lungs. The goal of this study is to find drug combinations that either stop the growth of spread or that work to shrink the spread by stimulating the immune system to control the cancer. More information on the trial and eligibility is available online.

New Chemotherapy Treatment for Solid Tumors (ART 207)

This clinical trial evaluates the effectiveness of a new formulation of an old chemotherapy drug, paclitaxel, in dogs with a variety of different cancers including mast cell tumors, sarcomas and carcinomas. This new drug formulation is designed to selectively target the tumor cells and avoid normal tissues to hopefully reduce side effects while increasing chemotherapy delivery to the tumor. More information on the trial and eligibility is available online.

Explore further: A common enemy: Through clinical trials, veterinarian fights cancer in animals, humans

Related Stories

Cancer drug first tested in pet dogs begins human trials

February 26, 2015

A new drug that prompts cancer cells to self-destruct while sparing healthy cells is now entering phase I clinical trials in humans. The drug, called PAC-1, first showed promise in the treatment of pet dogs with spontaneously ...

Recommended for you

How plants bind their green pigment chlorophyll

October 19, 2018

Chlorophyll is the pigment used by all plants for photosynthesis. There are two versions, chlorophyll a and chlorophyll b. These are structurally very similar to one another but have different colors, blue-green and yellowish ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.